Abbott's board authorizes repurchase of up to $3 billion of common stock

Abbott's (NYSE: ABT) board of directors has approved a new share repurchase program and declared a quarterly common dividend.

Abbott's board has authorized the repurchase of up to $3 billion of the corporation's common stock. The program replaces the previous $5 billion program that was announced in October 2008 and was recently completed. The purchases may be made from time to time as market conditions warrant and subject to regulatory considerations.

The board also declared a quarterly common dividend of 14 cents per share. This marks the 358th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable August 15, 2013, to shareholders of record at the close of business on July 15, 2013.

Abbott's strong cash flow has enabled it to invest in its business and return cash to shareholders through dividends and share repurchases. Abbott has a long history of returning value to shareholders, and since 2002, the company has delivered $31 billion in cash to its shareholders through dividends and share buybacks.

Abbott has increased its dividend payout for 41 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for 25 consecutive years.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.